Millions of Americans are experimenting with GLP-1 medications for various purposes, but scientific research hasn't caught up to understand all the effects. This widespread use is happening faster than studies can be conducted to fully evaluate safety and effectiveness.
Posts published in “GLP-1”
Millions of Americans are using GLP-1 weight loss drugs like Ozempic, but scientific research hasn't caught up to understand all the effects. This widespread real-world use is happening faster than formal studies can track safety and effectiveness.
Most people who start GLP-1 medications eventually quit them, and many plan to restart later, creating a cycle of stopping and starting. Research hasn't yet shown what health impacts this on-and-off pattern might have, though it's not recommended by doctors.
Stanford researchers discovered a compound that mimics Ozempic's weight loss effects without common side effects in mice studies. The treatment caused 3 grams of weight loss primarily from fat, with no changes in movement, digestion, or anxiety-like behaviors.
While most people lose weight on GLP-1 medications, new research shows these drugs may provide health benefits even for those who don't shed pounds. The medications appear to have positive effects beyond just weight reduction.
New research reveals why Ozempic and Wegovy don't work for about 10% of users - they have genetic variants that create 'GLP-1 resistance.' These individuals produce higher levels of certain proteins that interfere with the medications' effectiveness.
Indian pharmaceutical companies are launching cheaper generic versions of GLP-1 drugs, creating a price war against Novo Nordisk's branded medications like Ozempic and Wegovy. This competition could make these weight-loss treatments more affordable globally.
A new approach to GLP-1 treatment is emerging where patients start with injections to lose weight, then switch to pills to maintain their results. This strategy could make long-term weight management more convenient and potentially more affordable.